AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 3.38 USD 2.74% Market Closed
Market Cap: 334.4m USD
Have any thoughts about
AC Immune SA?
Write Note

Intrinsic Value

ACIU's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ACIU stock under the Base Case scenario is 9.58 USD. Compared to the current market price of 3.38 USD, AC Immune SA is Undervalued by 65%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ACIU Intrinsic Value
9.58 USD
Undervaluation 65%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
AC Immune SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ACIU cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ACIU?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
AC Immune SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about AC Immune SA

Provide an overview of the primary business activities
of AC Immune SA.

What unique competitive advantages
does AC Immune SA hold over its rivals?

What risks and challenges
does AC Immune SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for AC Immune SA.

Provide P/S
for AC Immune SA.

Provide P/E
for AC Immune SA.

Provide P/OCF
for AC Immune SA.

Provide P/FCFE
for AC Immune SA.

Provide P/B
for AC Immune SA.

Provide EV/S
for AC Immune SA.

Provide EV/GP
for AC Immune SA.

Provide EV/EBITDA
for AC Immune SA.

Provide EV/EBIT
for AC Immune SA.

Provide EV/OCF
for AC Immune SA.

Provide EV/FCFF
for AC Immune SA.

Provide EV/IC
for AC Immune SA.

Show me price targets
for AC Immune SA made by professional analysts.

What are the Revenue projections
for AC Immune SA?

How accurate were the past Revenue estimates
for AC Immune SA?

What are the Net Income projections
for AC Immune SA?

How accurate were the past Net Income estimates
for AC Immune SA?

What are the EPS projections
for AC Immune SA?

How accurate were the past EPS estimates
for AC Immune SA?

What are the EBIT projections
for AC Immune SA?

How accurate were the past EBIT estimates
for AC Immune SA?

Compare the revenue forecasts
for AC Immune SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of AC Immune SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of AC Immune SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of AC Immune SA compared to its peers.

Compare the P/E ratios
of AC Immune SA against its peers.

Discuss the investment returns and shareholder value creation
comparing AC Immune SA with its peers.

Analyze the financial leverage
of AC Immune SA compared to its main competitors.

Show all profitability ratios
for AC Immune SA.

Provide ROE
for AC Immune SA.

Provide ROA
for AC Immune SA.

Provide ROIC
for AC Immune SA.

Provide ROCE
for AC Immune SA.

Provide Gross Margin
for AC Immune SA.

Provide Operating Margin
for AC Immune SA.

Provide Net Margin
for AC Immune SA.

Provide FCF Margin
for AC Immune SA.

Show all solvency ratios
for AC Immune SA.

Provide D/E Ratio
for AC Immune SA.

Provide D/A Ratio
for AC Immune SA.

Provide Interest Coverage Ratio
for AC Immune SA.

Provide Altman Z-Score Ratio
for AC Immune SA.

Provide Quick Ratio
for AC Immune SA.

Provide Current Ratio
for AC Immune SA.

Provide Cash Ratio
for AC Immune SA.

What is the historical Revenue growth
over the last 5 years for AC Immune SA?

What is the historical Net Income growth
over the last 5 years for AC Immune SA?

What is the current Free Cash Flow
of AC Immune SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for AC Immune SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
AC Immune SA

Current Assets 187.6m
Cash & Short-Term Investments 157.9m
Receivables 26.2m
Other Current Assets 3.4m
Non-Current Assets 56.7m
Long-Term Investments 415k
PP&E 5.8m
Intangibles 50.4m
Current Liabilities 101m
Accounts Payable 1.4m
Accrued Liabilities 12.9m
Other Current Liabilities 86.7m
Non-Current Liabilities 13.1m
Long-Term Debt 2.4m
Other Non-Current Liabilities 10.7m
Efficiency

Earnings Waterfall
AC Immune SA

Revenue
41m CHF
Operating Expenses
-78.3m CHF
Operating Income
-37.3m CHF
Other Expenses
-2.6m CHF
Net Income
-39.9m CHF

Free Cash Flow Analysis
AC Immune SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ACIU Profitability Score
Profitability Due Diligence

AC Immune SA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROIC is Increasing
ROE is Increasing
31/100
Profitability
Score

AC Immune SA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

ACIU Solvency Score
Solvency Due Diligence

AC Immune SA's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
47/100
Solvency
Score

AC Immune SA's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ACIU Price Targets Summary
AC Immune SA

Wall Street analysts forecast ACIU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACIU is 10.46 USD with a low forecast of 8.08 USD and a high forecast of 16.8 USD.

Lowest
Price Target
8.08 USD
139% Upside
Average
Price Target
10.46 USD
209% Upside
Highest
Price Target
16.8 USD
397% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ACIU?

Click here to dive deeper.

Dividends

AC Immune SA
does not pay dividends
Shareholder Yield

Current shareholder yield for ACIU is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

ACIU News

Profile

AC Immune SA Logo
AC Immune SA

Country

Switzerland

Industry

Biotechnology

Market Cap

335.3m USD

Dividend Yield

0%

Description

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Contact

VAUD
Lausanne
EPFL Innovation Park, Building B
+41213459121.0
www.acimmune.com

IPO

2016-09-23

Employees

143

Officers

Co-Founder, CEO & Director
Dr. Andrea Pfeifer Ph.D.
CFO & VP of Finance
Mr. Christopher Roberts
Chief Technical Operations Officer
Mr. Piergiorgio Donati
Chief Administrative Officer
Mr. Jean-Fabien Monin
Chief HR Officer
Mr. Howard Donovan
Chief Scientific Officer
Ms. Madiha Derouazi
Show More
Senior VP of Investor Relations & Corporate Communications
Dr. Gary Anthony Waanders Ph.D.
General Counsel
Mr. Alexandre Caratsch
VP of U.S. Finance & Corporate Development
Mr. Julian Snow
Head of AD - SME
Dr. David T. Hickman
Show Less

See Also

Discover More
What is the Intrinsic Value of one ACIU stock?

The intrinsic value of one ACIU stock under the Base Case scenario is 9.58 USD.

Is ACIU stock undervalued or overvalued?

Compared to the current market price of 3.38 USD, AC Immune SA is Undervalued by 65%.

Back to Top